Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04982926 · ClinicalTrials.gov registry record · Phase 1
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
A Phase 1 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT04982926 is a Phase 1 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 29 participants.
The verdict
NCT04982926, a Phase 1 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.
Interventions
- DRUG TAS2940
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2025-03-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04982926
The ClinicalTrials.gov registry entry for NCT04982926 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAS2940 is the first listed.
NCT04982926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04982926 about?
NCT04982926 is a clinical study titled "A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer". This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.
What is the current status of trial NCT04982926?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2021-09-16. Estimated completion is 2025-03-24.
What interventions are being tested in trial NCT04982926?
The interventions under investigation include: TAS2940 (DRUG).
Who is sponsoring clinical trial NCT04982926?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.